Toxic Effects Associated With the Administration of Deferoxamine in the Premature Baboon With Hyaline Membrane Disease

R. A. DeLemos, James A de Lemos, J. J. Coalson, J. A. DeLemos, D. M. Null, D. R. Gerstmann

Research output: Contribution to journalArticlepeer-review

36 Scopus citations

Abstract

• We hypothesized that administration of the iron chelator deferoxamine would inhibit iron-catalyzed free radical generation and lessen the severity of oxygeninduced pulmonary injury. To evaluate its efficacy and safety in premature infants, we administered deferoxamine by intravenous infusion to five premature baboons with hyaline membrane disease supported with conventional ventilation and 100% oxygen for 6 days. Seven animals served as controls. Deferoxamine treatment was initiated at 10 mg/kg per hour but, after the precipitous death of the first animal, was progressively reduced to 1.25 mg/kg per hour in the other animals. Four of five deferoxamine-treated baboons developed cardiovascular collapse and all five died by 42 hours. Five of the seven control animals survived the 6-day expermental period. Since cardiovascular toxic effects have not previously been reported, these findings suggest unique vulnerability of the immature cardiovascular system to iron chelation.

Original languageEnglish (US)
Pages (from-to)915-919
Number of pages5
JournalAmerican Journal of Diseases of Children
Volume144
Issue number8
DOIs
StatePublished - Aug 1990

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Fingerprint

Dive into the research topics of 'Toxic Effects Associated With the Administration of Deferoxamine in the Premature Baboon With Hyaline Membrane Disease'. Together they form a unique fingerprint.

Cite this